Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: A multinational observational cohort study
Ann Rheum Dis. 2024 Feb 29:ard-2023-225369 doi: 10.1136/ard-2023-225369 Epub ahead of print
Flare risk did not increase following glucocorticoid tapering in modified serologically active clinically quiescent patients with SLE. They also found that antimalarial use was associated with decreased flare risk.
Katsumata, et al. followed participants selected from the Asia Pacific Lupus Collaboration patient cohort between 2013 and 2020. The primary outcome was disease flare, with flares divided into severe flares and overall flares. Renal flares were independently analysed as an exploratory outcome.
